Plain-English translation of NCT02951754 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing methylphenidate, a common medication used to treat ADHD in both children and adults. While this medication helps many people manage their ADHD symptoms, not everyone responds to it in the same way—some people need higher doses, some experience side effects, and some don't feel much benefit at all. This study aims to understand which patients will benefit most from this treatment and why.
Doctors have noticed that people respond very differently to this medication—some improve dramatically while others see little change, even at the same dose. By studying a large group of patients, researchers hope to identify the patterns and factors (including genetic ones) that predict whether someone will have a good response to this treatment.
You likely qualify if…
You likely don't qualify if…
You would start taking immediate-release medication in low doses (10 mg, two to three times daily) and gradually increase the dose each week until your ADHD symptoms improve and stabilize. Throughout the study, researchers would monitor how well the medication works for you, how you tolerate it, and collect information about your genetics and personal factors that might help explain why some people respond better than others.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Brazil